Docoh
Loading...

IMTX Immatics

News

From Benzinga Pro
Immatics Biotechnologies Granted U.S. Patent #11,214,604 'Peptides for use in immunotherapy against cancers'
4 Jan 22
News
View Patent here
Immatics Biotechnologies Granted U.S Patent #11,208,434 'Immunotherapy against several tumors including neuronal and brain tumors'
28 Dec 21
News
View Patent here
Immatics Biotechnologies Granted U.S. Patent #11,197,89 'Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers'
14 Dec 21
News
View Patent Here
Immatics Q3 Sales $7.40M Down From $9.10M YoY
16 Nov 21
Earnings, News
Immatics (NASDAQ:IMTX) reported $7.40 million in sales this quarter. This is a 18.68 percent decrease over sales of $9.10 million the same period last year.
Immatics Unveils Early-Stage Data Of TCR-Engineered Cell Therapy In Solid Tumors
9 Nov 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
9 Nov 21
Biotech, News, FDA, General
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across
Immatics To Present Update On Lead ACTengine Program IMA203 Targeting PRAME At The Society For Immunotherapy Of Cancer's 36th Annual Meeting
1 Nov 21
News, Events
Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company